Secretases as therapeutic targets in Alzheimer’s disease: patents 2000 – 2004

Bibliography

• LARNER AJ, ROSSOR MN: Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid 13-peptides. Expert Opin. Titer. Patents (1997) 7(10):1115–1127.
   Web of Science ®Google Scholar
• LARNER Al: Alzheimer's disease: targets for drug development. Mini Rev Med. Chem. (2002) 2:1–9.
   PubMedGoogle Scholar
• HARDY I, ALLSOP D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. (1991) 12:383–388.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA PV, GROWDON JH, HEDLEY-WHITE ET, HYMAN BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631–639.
   PubMed Web of Science ®Google Scholar
• McLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of AP amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol (1999) 46:860–866.
   PubMed Web of Science ®Google Scholar
• LUE LF, KUO YM, ROHER AE et al.: Soluble amyloid 13 peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol (1999) 155:853–862.
   PubMed Web of Science ®Google Scholar
• NASLUND J, HAROUTUNIAN V, MOHS R et al: Correlation between elevated levels of amyloid 3-peptide in the brain and cognitive decline. JAMA (2000) 283:1571–1577.
   PubMed Web of Science ®Google Scholar
• SISODIA SS: 3-Amyloid precursor proteincleavage by a membrane-bound protease. Proc. Nati Acad. Sci. USA (1992) 89:6075–6079.
   PubMed Web of Science ®Google Scholar
• LU DC, RABIZADEH S, CHANDRA S et al.: A second cytotoxic proteolytic peptide derived from amyloid 3-protein precursor. Nat. Med. (2000) 6:397–404.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Hypothesis: physiological and pathological interrelationships of amyloid 3-peptide and the amyloid precursor protein. Bioessays (1995) 17:819–824.
   PubMed Web of Science ®Google Scholar
• LORENZO A, YUAN M, ZHANG Z et al.: Amyloid 3 interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat. Neurosci. (2000) 3:460–464.
   PubMed Web of Science ®Google Scholar
• LU DC, SHAKED GM, MASLIAH E, BREDESEN DE, KOO EH: Amyloid 3-protein toxicity mediated by the formation of amyloid-3 protein precursor complexes. Ann. Nemo]. (2003) 54:781–789.
   PubMedGoogle Scholar
• GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F 3-amyloid precursor protein. Nature (1995) 373:523–527.
   PubMed Web of Science ®Google Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al: Correlative memory deficits, AP elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• WOLFE MS: The secretases of Alzheimer's disease. Carr. Top. Dev. Biol. (2003) 54:233–261.
   PubMed Web of Science ®Google Scholar
• VASSAR R, BENNETT BD, BABU-KHAN S et al.: P-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286:735–741.
   PubMed Web of Science ®Google Scholar
• SINHA S, ANDERSON JP, BARBOUR Ret al.: Purification and cloning of amyloid precursor protein 13-secretase from human brain. Nature (1999) 402:537–540.
   Google Scholar
• YAN R, BIENKOWSKI MJ, SHUCK ME et al.: Membrane-anchored aspartyl protease with Alzheimer's disease P-secretase activity. Nature (1999) 402:533–537.
   PubMed Web of Science ®Google Scholar
• HUSSAIN I, POWELL D, HOWLETT DR et al.: Identification of a novel aspartic protease (Asp2) as P-secretase. Ma Cell. Neurosci. (1999) 14:419–427.
   PubMed Web of Science ®Google Scholar
• SKOVRONSKY DM, LEE VM-Y: P-Secretase revealed: starting gate for race to novel therapies for Alzheimer's disease. Trends Phannacol Sci. (2000) 21:161–163.
   PubMedGoogle Scholar
• CAI H, WANG Y, MCCARTHY D et al: BACE1 is the major P-secretase for generation of AP peptides by neurons. Nat. Neurosci. (2001) 4:233–234.
   PubMed Web of Science ®Google Scholar
• FARZAN M, SCHNITZLER CE, VASILIEVA N, LEUNG D, CHOE H: BACE2, a P-secretase homolog, cleaves at the 3-site and within the amyloid-3 region of the amyloid 13 precursor protein. Proc. Natl. Acad. Sci. USA (2000) 97:9712–9717.
   PubMed Web of Science ®Google Scholar
• SOLANS A, ESTIVILL X, DE LA LUNA S: A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein P-secretase. Cytogenet. Cell Genet. (2000) 89:177–184.
   Google Scholar
• BENNETT BD, BABU-KHAN S, LOELOFF R et al: Expression analysis of BACE2 in brain and peripheral tissues. Biol Chem. (2000) 275:20647–20651.
   Web of Science ®Google Scholar
• HOLSINGER RIAD, MCLEAN CA, BEYREUTHER K, MASTERS CL, EVIN G: Increased expression of the amyloid precursor P-secretase in Alzheimer's disease. Ann. Neurol (2002) 51:783–786.
   PubMedGoogle Scholar
• •The first of four reports of elevated levels of P-secretase in AD brain tissue, suggesting this was a potential therapeutic target in AD.
   Google Scholar
• FUKUMOTO H, CHEUNG BS, HYMAN BT, IRIZARRY MC: P-Secretase protein and activity are increased in the neocortex in Alzheimer's disease. Arch. Neurol (2002) 59:1381–1389.
   PubMed Web of Science ®Google Scholar
• •See note for [25].
   Google Scholar
• TYLER SJ, DAWBARN D, WILCOCK GK, ALLEN SJ: a- and P-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. (2002) 299:373–376.
   PubMed Web of Science ®Google Scholar
• •See note for [25].
   Google Scholar
• YANG LB, LINDHOLM K, YAN R et al.: Elevated P-secretase expression and enzymatic activity detected in sporadic Alzheimer's disease. Nat. Med. (2003) 9:3–4.
   PubMed Web of Science ®Google Scholar
• •See note for [25].
   Google Scholar
• GATTA LB, ALBERTINI A, RAVID R, FINAZZI D: Levels of P-secretase BACE and a-secretase ADAM10 mRNAs in Alzheimer hippocampus. Neuroreport (2002) 15:2031–2033.
   Google Scholar
• LUO Y, BOLON B, KAHN S et al: Mice deficient in BACE1, the Alzheimer's P-secretase, have normal phenotype and abolished 3-amyloid generation. Nat. Neurosci. (2001) 4:231–232.
   PubMed Web of Science ®Google Scholar
• ROBERDS SL, ANDERSON J, BASI G et al.: BACE knockout mice are healthy despite lacking the primary P-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Ma Genet. (2001) 10:1317–1324.
   PubMed Web of Science ®Google Scholar
• HARRISON SM, HARPER AJ, HAWKINS J et al.: BACE1 (P-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Ma Cell. Neurosci. (2003) 24:646–655.
   PubMed Web of Science ®Google Scholar
• LICHTENTHALER SF, DOMINGUEZ DI, WESTMEYER GG et al.: The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. 1 Biol. Chem. (2003) 278:48713–48719.
   Google Scholar
• DE STROOPER B, SAFTIG P, GAESSAERTS K et al: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 391:387–390.
   PubMed Web of Science ®Google Scholar
• KIMBERLY WT, LAVOIE MJ, OSTASZEWSKI BL et al.: y-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. USA (2003) 100:6382–6387.
   PubMed Web of Science ®Google Scholar
• DE STROOPER B: Aph-1, Pen-2, and nicastrin with presenilin generate an active y-secretase complex. Neuron (2003) 38:9–12.
   PubMed Web of Science ®Google Scholar
• XU M, LIA MT, HUANG Q et al.: y-Secretase: characterization and implication for Alzheimer's disease therapy. Neurobiol Aging (2002) 23:1023–1030.
   PubMed Web of Science ®Google Scholar
• HAASS C, STEINER H: Alzheimer's disease y-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. (2002) 12:556–562.
   PubMed Web of Science ®Google Scholar
• SELKOE D, KOPAN R: Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Ann. Rev Neurosci. (2003) 26:565–597.
   PubMed Web of Science ®Google Scholar
• SCHEUNER D, ECKMAN C, JENSEN M et al.: Secreted amyloid 3-protein similar to that in the amyloid plaques of Alzheimer's disease is increased in vivo by the presenilin-1 and -2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. (1996) 2:864–870.
   PubMed Web of Science ®Google Scholar
• SCHROETER EH, ILAGAN MX, BRUNKAN AL et al.: A presenilin dimer at the core of the y-secretase enzyme: insights from parallel analysis of Notch-1 and APP proteolysis. Proc. Natl. Acad. Sci. USA (2003) 100:13075–13080.
   PubMedGoogle Scholar
• DERMAUT B, KUMAR-SINGH S, ENGELBORGHS S et al: A novel presenilin-1 mutation associated with Pick's disease but not 3-amyloid plaques. Ann. Neural. (2004) 55:617–626.
   PubMed Web of Science ®Google Scholar
• SHEN J, BRONSON RT, CHEN DF et al.: Skeletal and CNS defects in presenilin-l-deficient mice. Cell (1997) 89:629–639.
   PubMed Web of Science ®Google Scholar
• WOLFE MS, CITRON M, DIEHL TS, XIA W, DONKOR 10, SELKOE DJ: A substrate-based difluoro ketone selectively inhibits Alzheimer's y-secretase activity. J. Med. Chem. (1998) 41:6–9.
   PubMed Web of Science ®Google Scholar
• DOVEY HF, JOHN V, ANDERSON JP et al.: Functional y-secretase inhibitors reduce 3-amyloid peptide levels in brain. Neurochem. (2001) 76:173–181.
   PubMed Web of Science ®Google Scholar
• LANZ TA, HIMES CA, PALLANTE G et al.: The y-secretase inhibitor N-(N-(3,5-difluorophenacety1)-L-alany0-S phenylglycine t-butyl ester reduces Ap levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol Exp. Ther: (2003) 305:864–871.
   Google Scholar
• MARJAUX E, HARTMANN D, DE STROOPER B: Presenilins in memory, Alzheimer's disease, and therapy. Neuron (2004) 42:189–192.
   PubMedGoogle Scholar
• WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the y-secretase inhibitor LY-411,575 inhibits 3-amyloid peptide production and alters lymphopoiesis and intestinal cell differentation. Biol. Chem. (2004) 279:12876–12882.
   Google Scholar
• SKOVRONSKY DM, MOORE DB, MILLA ME, DOMS RW, LEE VM-Y: Protein kinase C-dependent a-secretase competes with P-secretase for cleavage of amyloid-3 precursor protein in the trans-golgi network. J. Biol. Chem. (2000) 275:2568–2575.
   PubMed Web of Science ®Google Scholar
• MASASHI A, HATTORI C, SZABO B et al.: Putative function of ADAM9, ADAM10, and ADAM17 as APP a-secretase. Biochem. Biophys. Res. Commun. (2003) 301:231–235.
   PubMedGoogle Scholar
• ALLINSON TMJ, PARKIN ET, TURNER AJ, HOOPER NM: ADAMs family members as amyloid precursor protein a-secretases. Neurosci. Res. (2003) 74:342–352.
   Google Scholar
• POSTINA R, SCHROEDER A, DEWACHTER I et al.: A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model. .1 Clin. Invest. (2004) 113:1456–1464.
   Google Scholar
• •V7171 transgenic mice overexpressing ADAM10 (an a-secretase) showed reduced AB and plaque burden in comparison to V7171 animals, and alleviated deficits in LTE Increased plaque burden was seen in animals with catalytically inactive ADAM10. The most compelling evidence to date that a-secretase modulation could impact on the pathogenesis of AD and hence is a viable therapeutic target.
   Google Scholar
• HARTMANN D, DE STROOPER B, SERNEELS L et al.: The disintegrin/ metalloproteinase ADAM10 is essential for Notch signalling but not for a-secretase activity in fibroblasts. Hum. Mol. Genet. (2002) 11:2615–2624.
   PubMed Web of Science ®Google Scholar
• KOJRO E, GIMPL G, LAMMICH S, MARZ W, FAHRENHOLZ F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the a-secretase ADAM10. Proc. Nati Acad. Sci. USA (2001) 98:5815–5820.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B, KELLMAN W, RUOSSEAU P, CELESIA GG, SIEGEL G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neural. (2000) 57:1439–1443.
   PubMed Web of Science ®Google Scholar
• JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA: Statins and the risk of dementia. Lancet (2000) 356:1627–1631.
   PubMed Web of Science ®Google Scholar
• ROCKWOOD K, KIRKLAND S, HOGAN DB et al.: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. (2002) 59:223–227.
   PubMed Web of Science ®Google Scholar
• ZAMRINI E, MCGWIN G, ROSEMAN JM: Association between statin use and Alzheimer's disease. Neuroepidemiology (2004) 23:94–98.
   PubMed Web of Science ®Google Scholar
• TUNG JS, DAVIS DL, ANDERSON JPet al.: Design of substrate-based inhibitors of human I3-secretase. Med. Chem. (2002) 45:259–262.
   Google Scholar
• NO AUTHORS LISTED: Statin-derived tetrapeptide inhibitors of I3-secretase. Expert Opin. Ther. Patents (2001) 11(6):1047–1050.
   Google Scholar
• HOM RK, FANG LY, MAMO S et al: Design and synthesis of statine-based permeable peptidomimetic inhibitors of human 13 secretase..I. Med. Chem. (2003) 46:1799–1802.
   PubMed Web of Science ®Google Scholar
• HOM RK, GAILUNAS AF, MAMO S et al.: Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human I3-secretase. Med. Chem. (2004) 47:158–164.
   Google Scholar
• •Report of hydroxyethylene transition state isosteres, small molecules with potent BACE inhibitory activity but enhanced cell penetration.
   Google Scholar
• ABBENANTE G, KOVACS DM, LEUNG DL, CRAIK DJ, TANZI RE, FAIRLIE DP: Inhibitors of 13-amyloid formation based on the I3-secretase cleavage site. Biochem. Biophys. Res. Commun. (2000) 268:133–135.
   PubMed Web of Science ®Google Scholar
• ERMOLIEFF J, LOY JA, KOELSCH G, TANG J: Proteolytic activation of recombinant pro-memapsin 2 (pro-I3-secretase) studied with new fluorogenic substrates. Biochemistry (2000) 39:12450-12456 [Erratum Biochemistry (2000) 39:16263].
   Google Scholar
• SHEARMAN MS, BEHER D, CLARKE EE et al: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid I3-protein precursor y-secretase activity. Biochemistry (2000) 39:8698–8704.
   PubMed Web of Science ®Google Scholar
• ZHANG L, SONG L, TERRACINA G, LIU Y, PRAMANIK B, PARKER E: Biochemical characterization of the y-secretase activity that produces 3-amyloid peptides. Biochemistry (2001) 40:5049–5055.
   PubMedGoogle Scholar
• BARTEN DM, GUSS VL, CORSA JA et al: I3-amyloid reductions in brain, plasma and CSF of a transgenic mouse model of Alzheimer's disease with a y-secretase inhibitor. Neurobiol. Aging (2004) 25(82):582.
   Google Scholar
• SIEMERS E, DEAN RA, SATTERWHITE J et al.: Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid 13 concentrations after administration of a functional y-secretase inhibitor in healthy volunteers. Neurobiol. Aging (2004) 25(S2):5569–5570.
   Google Scholar
• HOCK C, MADDALENA A, RASCHIG A et al.: Treatment with the selective M1 agonist talsaclidine decreases cerebrospinal fluid levels of A1342 in patients with Alzheimer's disease. Amyloid (2003) 10:1–6.
   PubMed Web of Science ®Google Scholar
• LAHIRI DK, GE Y-W, FARLOW MR: Studies with the memory enhancing drug AIT-082 in PC12 cells. In: Alzheimer's Disease: Advances in Etiology Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds) Chichester, Wiley (2001):759–767.
   Google Scholar
• GRUNDMAN M, FARLOW M, PEAVY G et al.: A Phase I study of AIT-082 in healthy elderly volunteers. .1 Mol. Neurosci. (2002) 18:283–293.
   Google Scholar
• GRUNDMAN M, CAPPARELLI E, KIM HT et al.: A multicenter, randomized, placebo-controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. (2003) 73:539–553.
   PubMed Web of Science ®Google Scholar
• LARNER AJ, DORAN M: Prion diseases: update on therapeutic patents, 1999-2002. Expert Opin. The]: Patents (2003) 13(1):67–78.
   Google Scholar
• TAMAMURA H, KATO T, OTAKA A, FUJII N: Synthesis of potent I3-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org. Biomol. Chem. (2003) 1:2468–2473.
   PubMed Web of Science ®Google Scholar
• •Report of hydroxyethylarnine dipeptide isosteres, with IC 50 values of 100 nM.
   Google Scholar
• SHUTO D, KASAI S, KIMURA T et al: KMI-008, a novel I3-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg. Med. Chem. Lett. (2003) 13:4273–4276.
   PubMed Web of Science ®Google Scholar
• •Report of hydroxymethylcarbonyl transition state isosteres, such as phenylnorstatine, as P-secretase inhibitors.
   Google Scholar
• CHANG W-P, KOELSCH G, WONG S et al: In vivo inhibition of brain A13 level by memapsin 2 (I3-secretase) inhibitors. Neurobiol. Aging (2004) 25(52):5581.
   Google Scholar
• WONG PC, CAI H, LAIRD FM et a/.: A role for APP and BACE1 in cognition. Neurobiol. Aging (2004) 25(82):52.
   Google Scholar
• WEGGEN S, ERIKSEN JL, PAS P et al: A subset of NSAIDs lower amyloidogenic A1342 independently of cyclooxygenase activity. Nature (2001) 414:212–216.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI Y, HAYASHI I, TOMINARI Y et al: Sulindac sulfide is a non-competitive y-secretase inhibitor that preferentially reduces A1342 generation. J. Biol. Chem. (2003) 278:18664–18670.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Cholinesterase inhibitor use at a cognitive function clinic. Frog. Neurol Psychiatr. (2004) 8(4):14,18,20.
   Google Scholar
• HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against P-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547–554.
   PubMed Web of Science ®Google Scholar
• GILMAN S, KOLLER M, BLACK RS et al.: Neuropsychological, CSF, and neuropathological effects of AP immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol Aging (2004) 25(S2):S84.
   Google Scholar
• NICOLL JAR, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-P peptide: a case report. Nat. Med. (2003) 9:448–452.
   PubMedGoogle Scholar
• FERRER I, BRADA-ROVIRA M, SANCHEZ-GUERRA ML, REY JL, COSTA-JUSSA F: Neuropathology and pathogenesis of encephalitis following amyolid-P immunization in Alzheimer's disease. Brain Athol (2004) 14:11–20.
   PubMed Web of Science ®Google Scholar